1. Home
  2. ECBK vs SKYE Comparison

ECBK vs SKYE Comparison

Compare ECBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

HOLD

Current Price

$17.32

Market Cap

153.5M

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.03

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECBK
SKYE
Founded
1919
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
44.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ECBK
SKYE
Price
$17.32
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
14.4K
528.9K
Earning Date
02-04-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
104.95
N/A
EPS
0.80
N/A
Revenue
$29,860,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.49
N/A
Revenue Growth
20.84
N/A
52 Week Low
$12.56
$0.68
52 Week High
$17.75
$5.75

Technical Indicators

Market Signals
Indicator
ECBK
SKYE
Relative Strength Index (RSI) 51.18 49.42
Support Level $17.25 $0.68
Resistance Level $17.39 $0.95
Average True Range (ATR) 0.14 0.12
MACD -0.02 0.02
Stochastic Oscillator 16.47 67.03

Price Performance

Historical Comparison
ECBK
SKYE

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: